HTA changes at EU level could slow the uptake of new cell and gene therapies, industry group warns
If a cell or gene therapy developer wants to bring a new product to market in Europe, first they have to clear the EMA, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
